Vyant Bio, Inc. Common Stock
VYNT
VYNT was delisted on the 12th of May, 2023.
29 hedge funds and large institutions have $19.8M invested in Vyant Bio, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 6 closing their positions.
217% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 6
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
174% more capital invested
Capital invested by funds: $7.21M → $19.8M (+$12.5M)
81% more funds holding
Funds holding: 16 → 29 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$5.1M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$2.18M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.98M |
| 4 |
GMCM
Gruber & McBaine Capital Management
San Francisco,
California
|
+$1.21M |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$1.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$916K |
| 2 |
Jane Street
New York
|
-$558K |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$334K |
| 4 |
MA
MUFG Americas
New York
|
-$328K |
| 5 |
Morgan Stanley
New York
|
-$143K |
VYNT Hedge Fund Activity: Q4 2013 in Review
29 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Vyant Bio, Inc. Common Stock (VYNT) for Q4 2013, worth a combined $19.8M — up 174% from $7.21M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new VYNT positions and 6 closed out — a net gain of 13 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $5.1M. The largest seller was EAM Investors, exiting entirely with an estimated $916K sold.
- 29 institutional investors held Vyant Bio, Inc. Common Stock (VYNT) as of Q4 2013, up from 16 in Q3 2013.
- Funds reported $19.8M of Vyant Bio, Inc. Common Stock stock for Q4 2013, up 174% quarter-over-quarter.
- 19 funds opened new Vyant Bio, Inc. Common Stock positions in Q4 2013 and 6 closed out, a net change of +13 holders.
- The largest Vyant Bio, Inc. Common Stock buyer in Q4 2013 was Deerfield Management, an estimated $5.1M added.
- The largest Vyant Bio, Inc. Common Stock seller in Q4 2013 was EAM Investors, an estimated $916K sold.
Based on aggregated 13F filings for Q4 2013.